Você procurou por: ctrough (Inglês - Maltês)

ctrough
(0.63-1.81)

ctrough (µg/ml)
ctrough (µg/ ml)

geometric mean ctrough (q2m) µg/ml
medja ġeometrika ta’ ctrough (q2m) µg/ml

and ctrough is expected to increase by 5%.
jiżdied minn 65 għal 200 kg, cmax huwa mistenni li jonqos b’ 24% u ctrough jiżdied b’ 5%.

ctrough values are not presented in the table because they are not available from all studies
valuri ta’ cthrough mhux ippreżentati fit-tabella peress li mhux disponibbli mill-istudji kollha

the fluctuations between cmax and ctrough were higher for the every 4 weeks dosage regimen.
il-varjazzjonijiet bejn cmax u ctrough kienu ogħla għall-iskeda ta’ dożaġġ ta’ kull 4 ġimgħat.

for subjects weighing  90 kg, ctrough values were the same for the intravenous and subcutaneous regimens.
għal individwi li jiżnu  90 kg, valuri ta’ ctrough kienu l-istess għall-korsijiet fil-vini u taħt il-ġilda.

similarly, for subjects in the high bsa tritile, ctrough values were the same for the intravenous and subcutaneous regimens.
b’mod simili, għal individwi fit-terz l-għoli tal-bsa, il-valuri ta’ ctrough kienu l-istess għall-korsijiet fil-vini u dawk taħt il-ġilda.

the objective of the part 1 was to select a mabthera subcutaneous formulation dose that resulted in comparable mabthera serum ctrough levels compared with mabthera intravenous formulation.
l-għan ta’ parti 1 kien li tiġi magħżula doża tal-formulazzjoni għall-għoti taħt il-ġilda ta’ mabthera li twassal għal livelli ta’ ctrough fis-serum ta’ mabthera komparabbli mal-formulazzjoni għall-għoti fil-vini ta’ mabthera.

as weight increases from 65 to 200 kg, cmax is expected to decrease 24% and ctrough is expected to increase by 5%.
meta l-piż jiżdied minn 65 għal 200 kg, cmax huwa mistenni li jonqos b’24% u ctrough jiżdied b’5%.

as compared to the bid regimen, the once daily dosing is associated with a reduction in the cmin/ctrough values of approximately 50%.
meta mqabbel mal-kors bid, id-dożaġġ ta’ darba kuljum hu assoċjat ma’ tnaqqis fil-valuri ta’ cmin/ctrough ta ‘ madwar 50%.

all but one of the patients achieved ctrough values of saquinavir above the therapeutic threshold (100 ng/ml) in the fasted state.
il- pazjenti kollha minbarra wieħed laħqu valuri ta’ ctrough ta’ saquinavir ’l fuq mill-limitu terapewtiku (100 ng/ml) fi stat sajjem.

as compared to the bid regimen, the once-daily dosing is associated with a reduction in the cmin/ctrough values of approximately 50%.
meta mqabbel ma dużaġġ bid, dużaġġ ta’ darba kuljum ġie assoċjat ma tnaqqis fil-valuri ta’ cmin/ctrough b’ approssimament 50%.

a to report analysis of primary endpoint (ctrough non-inferiority) for part 2 and available safety and immunogenicity data from both parts of the ongoing study.
a biex tirrapporta analiżi tal-punt finali primarju (nuqqas ta’ inferjorità ctrough) għall-parti 2 u dejta disponibbli dwar is-sigurtà u l-immunoġeniċità miż-żewġ partijiet tal-istudju li għaddej.

- saquinavir auc ↓ 51% saquinavir ctrough ↓ 49% (8 hours post dose) saquinavir cmax ↓ 54%.
mnaqqsa u t- telf tar- rispons viroloġiku u l- possibiltà ta ’ reżistenza għal wieħed jew aktar mill- komponenti tal- kors

in a crossover study in 60 healthy volunteers, intracellular lamivudine-tp pharmacokinetic parameters were similar (auc24,ss and cmax24,ss) or lower (ctrough – 24%) for the lamivudine 300 mg once daily regimen compared to the lamivudine 150 mg twice daily regimen.
fi studju crossover f’60 voluntier b’saħħithom, il-parametri farmakokinetiċi ta’ lamivudine-tp fiċ-ċelluli kienu simili (auc24,ss u cmax,ss) jew aktar baxxi (ctrough – 24%) għas-sistema ta’ kura ta’ lamivudine 300mg darba kuljum meta mqabbla mas-sistema ta’ kura ta’ lamivudine 150mg darbtejn kuljum.